

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are stated below next to my name:

I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

---

**NUCLEIC ACID AND AMINO ACID SEQUENCES OF INFECTIOUS SALMON  
ANAEMIA VIRUS AND THEIR USE AS VACCINES**

---

the specification of which is attached hereto unless the following box is checked

☒ was filed on August 7 2000 as Application No. \_\_\_\_\_ or PCT  
Application No. PCT/GB00/02976 and amended on February 6, 2002 (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S)**

COUNTRY/OFFICE	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
GB	9918588.6	August 7 1999	<input checked="" type="checkbox"/> YES NO <input type="checkbox"/>
GB	0005848.7	March 11 2000	<input checked="" type="checkbox"/> YES NO <input type="checkbox"/>
GB	0006674.6	March 21 2000	<input checked="" type="checkbox"/> YES NO <input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

**PROVISIONAL APPLICATION NUMBER**

**DATE OF FILING**

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS  
DESIGNATING THE U.S. FOR BENEFIT UNDER 25 U.S.C. §120**

**Status (check one)**

Application Serial No.	Date of Filing	Patented	Pending	Abandoned
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

And I hereby appoint Arthur H. Seidel, Registration No. 15,979; Gregory J. Lavorgna, Registration No. 30,469; Daniel A. Monaco, Registration No. 30,480; Thomas J. Durling, Registration No. 31,349; John J. Marshall, Registration No. 29,671; Joseph R. Delmaster, Jr., Registration No. 38,399, Robert E. Cannuscio, Registration No. 36,469, and George A. Frank, Registration No. 27,636, my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence to Drinker Biddle & Reath LLP, One Logan Square, 18<sup>th</sup> & Cherry Streets, Philadelphia, PA 19103-6996. Address all telephone calls to Daniel A. Monaco, (215) 988-3312 (telefax: (215) 988-2757).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**BEST AVAILABLE COPY**

**FULL NAME OF SOLE OR FIRST INVENTOR**

**STEVEN**

(GIVEN NAME)

(MIDDLE INITIAL OR NAME)

**GRIFFITHS**

(FAMILY OR LAST NAME)

Inventor's signature: \_\_\_\_\_

Date: \_\_\_\_\_

21/5/02

Country of Citizenship: Great Britain

Residence: Fredericton Canada

(City)

(State or Foreign Country)

Post Office Address: 367 Saunders Street  
Fredericton, New Brunswick E3B 6Z9  
CANADA

**FULL NAME OF SOLE OR SECOND INVENTOR**

**RACHEL**

(GIVEN NAME)

**JANE**

(MIDDLE INITIAL OR NAME)

**RITCHIE**

(FAMILY OR LAST NAME)

Inventor's signature: \_\_\_\_\_

Date: \_\_\_\_\_

21/5/02

Country of Citizenship: Great Britain

Residence: Hanwell Canada

(City)

(State or Foreign Country)

Post Office Address: 48 Eddington Road  
Hanwell E3E 2C9  
CANADA

**BEST AVAILABLE COPY**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF Griffiths et al.

Confirmation Number: 5927

APPLICATION NO: 10/049,086

Art Unit: 1645

FILED: May 30, 2002

Examiner: Joanne Stewart

**FOR: NUCLEIC ACID AND AMINO ACID SEQUENCES OF INFECTIOUS SALMON ANAEMIA VIRUS AND THEIR USES AS VACCINES**

Assistant Commissioner for Patents  
Washington, D.C. 20231

REVOCATION AND APPOINTMENT OF POWER OF ATTORNEY

We, the undersigned, are duly appointed officers of Novartis AG, located at Lichtstrasse 35, 4056 Basel, Switzerland, and have authority to sign on behalf of Novartis AG, the Assignee of the above referenced patent application. Novartis AG obtained all rights, title, and interest in the invention described and contained in the above referenced patent application through an Assignment of the inventor, Steven Gareth Griffiths, on May 21, 2002, and the inventor, Rachel Jane Ritchie, on May 21, 2002, this Assignment being recorded with the U.S. Patent and Trademark Office on June 5, 2002 at Reel/Frame 012960/0456.

Novartis AG hereby revokes all current Powers of Attorney and hereby appoints the attorneys and agents associated with Customer Number 001095 respectively and individually as Novartis AG's attorneys and agents, with full power for substitution and revocation, to prosecute this application and to transact all business with the U.S. Patent and Trademark Office connected therewith, and direct that all correspondence and communications be directed to the address associated with:

Customer Number 001095

which is currently:

Thomas Hoxie  
Novartis  
Corporate Intellectual Property  
One Health Plaza  
Building 430  
East Hanover, NJ 07936-1080

Novartis AG requests that the Examiner note the change in the Attorney Docket number for this patent application. Novartis AG kindly requests that the Examiner change the Attorney Docket from "43050-1" to "H-32318A" in all future correspondence.

Should the Examiner have any questions about this Revocation and Appointment of Power of Attorney, the Examiner is requested to contact David L. Marks, Registration No. 37,881, at 862-778-7922.

Respectfully submitted,

4/6/03  
Date

Ingrid Kelly  
Signature  
Name: INGRID KELLY SPILLMANN  
Title: AUTHORIZED SIGNATORY  
Novartis AG  
Lichtstrasse 35  
4056 Basel  
Switzerland

4/6/03  
Date

C. Bohmann  
Signature  
Name: CHRISTINE BOHMANN  
Title: AUTHORIZED SIGNATORY  
Novartis AG  
Lichtstrasse 35  
4056 Basel  
Switzerland